CAPR: Capricor Therapeutics Inc. Company Short-Term Debt

Capricor Therapeutics (CAPR) specializes in developing innovative exosome and cell therapy methods to combat muscle and heart pathologies, aiming for leadership in the regenerative sector. The anticipation of the BLA filing for its Duchenne muscular dystrophy drug serves as a key trigger, while production launch costs are already priced in. This chart of stock quotes on GURU.Markets confirms these trends, with the indicator standing at 0.00.

Fundamental asset selection requires a rigorous liquidity analysis through the lens of liabilities. This indicator measures the total amount of debt maturing within one year, determining the issuer's ability to withstand credit pressure. For Capricor Therapeutics (CAPR), which lacks a stable cash flow, this parameter is critically important. Dependence on partner advances leaves the company vulnerable to any funding gaps. The dynamics of these risks are clearly reflected in this short-term debt chart.